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compare overall hospital costs between the two cohorts, con-
trolling for differences in variable distribution. RESULTS: From
9234 patients who met the inclusion criteria, 4972 patients
(53.8%) were prescribed warfarin and 5727 (62.0%) were
females. Overall rate of secondary diagnosis of VTE was 0.08%
(seven of 9241 patients; two enoxaparin and ﬁve warfarin
patients). Apart from LOS (p = 0.8089), NSD (p = 0.2421), and
gender (p = 0.4223), distribution of age (p < 0.0001) and in-
hospital deaths (p = 0.0045) were found to be signiﬁcantly dif-
ferent between the two cohorts. Overall mean hospital costs 
were found to be different (p < 0.0001) ($11,723.3 for warfarin
patients versus $11,963.9 for enoxaparin patients), after con-
trolling for signiﬁcant differences. Enoxaparin patients incurred
higher Medical/Surgical supplies ($616.7) and drugs/pharmacy
($312.1) expenses, while warfarin patients incurred more on
Operating-and-Recovery rooms ($766.4), Medical/Surgical
acute units ($487.3), and Laboratory ($39.6). CONCLUSIONS:
Overall rate of secondary diagnosis of VTE is very low for ortho-
pedic patients given prophylaxis; however, warfarin prophylaxis
showed a higher rate. Enoxaparin demonstrated a better clinical
outcome, but warfarin was signiﬁcantly less expensive. Further
research is needed to reconcile the clinical versus ﬁnancial
outcome ﬁndings from these analyses.
ENDOCRINE DISORDERS
PEN1
COST SAVINGS ASSOCIATED WITH FINER DOSING
INCREMENTS THROUGH THE USE OF NORDITROPIN
NORDIFLEX® IN THE UNITED STATES
Joshi AV1, Gore T1, Russell MW2
1Novo Nordisk Inc, Princeton, NJ, USA; 2Boston Health Economics,
Inc, Waltham, MA, USA
Fixed dosing increments in injectable devices may lead to poten-
tial inefﬁciencies such as overdosing in weight-based regimens.
Finer dosing increments can reduce product wastage and trans-
late into cost savings. OBJECTIVE: To compare overdosage and
wastage (therefore cost) due to Norditropin NordiFlex® 5mg 
to that of other somatropin (human growth hormone, rDNA
origin) delivery systems (Norditropin NordiPen® 5mg,
Genotropin® 5mg, Humatrope® 6mg, and Nutropin® 10mg)
in children. METHODS: Total recommended daily dose of
somatropin was calculated over a range of body weights and
weight-based (mg/kg) dosing regimens. Only body weights
resulting in a daily dose up to the maximum allowable dose for
each delivery system were considered. The amount of product
dispensed at each dose was determined based on dosing incre-
ments for each delivery system. Dosing increments for
Norditropin NordiFlex® were 0.025mg, compared to 0.05–0.2
mg for other delivery systems. The amount of somatropin admin-
istered by Norditropin NordiFlex® and associated annual costs
were compared with other somatropin delivery systems. Drug
costs were based on current wholesale acquisition costs (WAC).
RESULTS: At a daily dose of 0.030mg/kg, product wastage in
Norditropin NordiFlex® was 5.3%, 3.8%, 3.8%, and 1.8%
lower than Humatrope®, Nutropin®, Genotropin® and
Norditropin NordiPen®, respectively. The annual cost due to
Norditropin NordiFlex® was estimated at $14,580, and was
$811, $570, $390, and $265 lower than Humatrope®,
Nutropin®, Genotropin®, and Norditropin NordiPen®, respec-
tively. Greater savings (7.3%) were seen in lower body-weight
groups. At a higher daily dose of 0.043mg/kg, product wastage
(and corresponding annual cost) in Norditropin NordiFlex® was
6.1% ($1006), 4.2% ($684), 4.2% ($491), and 2.2% ($358)
lower than Humatrope®, Nutropin®, Genotropin®, and
Norditropin NordiPen® respectively. CONCLUSION: Com-
pared to other delivery systems, Norditropin NordiFlex®
reduces overdosage and wastage of growth hormone, conse-
quently resulting in meaningful cost savings.
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About 20,000 children in the US receive somatropin (human
growth hormone, rDNA origin) for the treatment of growth
hormone deﬁciency (GHD), with approximately 4000 new cases
annually. While the cost-effectiveness of somatropin for the treat-
ment of GHD has been assessed in the UK, to our knowledge 
no estimates for the US have been reported. OBJECTIVE: To
generate estimates of cost-effectiveness/utility of Norditropin® 
(r-DNA somatropin) in the treatment of GHD in children.
METHODS: A decision-analytic model of the epidemiology and
treatment of GHD in children was developed. Treatment of
GHD was assessed in two hypothetical cohorts compared to no
treatment–treatment with Norditropin® 0.030mg/kg/day from
ages ﬁve through 16 years, and treatment from ages three
through 18 years. Costs included those related to drug acquisi-
tion, endocrinologist consultations, and primary care ofﬁce
visits. Estimates of patient weight by age and sex were derived
from published literature, as was the proportion of patients
achieving normal height through Norditropin® treatment and
pre/post-treatment patient utilities. Cost-effectiveness/utility was
estimated over patients’ expected lifetimes, and was stated alter-
natively as discounted (3% per annum) US dollars per normal
height year (NHY) gained, and cost per quality adjusted life-year
(QALY) gained. Multivariate sensitivity analyses were conducted
to ensure robustness of the model. RESULTS: The cost-
effectiveness and cost-utility of treating children from ages ﬁve
through 16 years with Norditropin® was estimated at $8909 per
NHY gained and $36,955 per QALY gained, respectively. Treat-
ment of children from ages three through 18 years was estimated
to cost $9277 per NHY gained and $42,556 per QALY gained.
Findings were relatively insensitive to variation in most model
parameters. CONCLUSION: For both age cohorts, the cost-
effectiveness/utility of Norditropin® in the treatment of GHD
compares favorably to well-accepted threshold values. Thus,
Norditropin® represents excellent value for money for the treat-
ment of GHD in children.
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OBJECTIVE: To derive health status values (utilities) for the
Swedish population. METHODS: EQ-5D data were collected
through a mailing survey to a random sample (n = 2990) of the
Swedish population (response rate 65%: complete data on 1741
(49.4% males; mean age 48.4). The model was estimated using
the Jackknife method and multiple regression analysis. The full
sample was randomly divided into 10 parts of approximately the
